Primary Care Alliance

Primary Care Alliance

Contact Us Join Today

Home | Archives for pcalliance

Moderna’s mNEXSPIKE Webinar | June 16-17, 2026

Moderna is hosting a webinar for health professionals on updates on its mNEXSPIKE (COVID-19, mRNA) on Tuesday, June 16, 2026, from 3:00 PM to 4:00 PM ET and Wednesday, June 17, 2026, from 12:00 PM to 1:00 PM ET.

In both sessions, presenters Dr. McKinney and Dr. Middleton will “review the evolving disease landscape, discuss the latest data on mNEXSPIKE (COVID-19 Vaccine, mRNA), and share clinical perspectives and best practices to support strong COVID-19 vaccine recommendations.” To view more details on Moderna’s upcoming webinar, click here.

Moderna’s mNexspike was approved by the FDA on May 31, 2025, for patients 65 years and older. Additionally, mNexspike is approved to be administered to patients 12 years and older with a high-risk condition. Asthma, cancer, diabetes, heart conditions, HIV, mental health conditions, obesity and many other diagnoses fall under the CDC’s list of high-risk conditions. To see the CDC’s complete list of high-risk conditions, please go here.

To register, click the buttons below to sign up for your preferred session

Tuesday, June 16, 2026
3:0‌0 to 4:0‌0 PM ET

Register Now

Wednesday, June 17, 2026
12:0‌0 to 1:0‌0 PM ET

Register Now

It’s time for clinics to prebook their COVID-19 vaccines for the 2026-2027 season. Primary Care Alliance contracts with Moderna, Pfizer, and Sanofi to offer our members the best possible prices on COVID-19 vaccines. This variety allows members to choose the vaccine products that best meet their patients’ needs.

COVID-19 Vaccine Vial

What COVID-19 Vaccine Options Are Available Through PCA?

Moderna offers multiple COVID-19 vaccine options, including Spikevax in formulations for different age groups and mNEXSPIKE for older adults and individuals at increased risk for severe COVID-19. Pfizer offers its COVID-19 vaccine, Comirnaty, in age-specific dosages. Through Sanofi, members can prebook Nuvaxovid, Novavax’s COVID-19 vaccine and the only non-mRNA, recombinant protein-based COVID-19 vaccine currently available.

For more information on how to prebook COVID-19 vaccines for the 2026-2027 season and the benefits of prebooking, click the button below to visit our 2026-2027 COVID-19 Vaccine Prebooking resource page.

2026-2027 COVID-19 Vaccine Prebooking Information

What Is the Current COVID-19 Vaccine Recommendation From the ACIP and CDC?

Although there has been much debate regarding vaccine recommendations this year, the most current Advisory Committee on Immunization Practices (ACIP) and Centers for Disease Control and Prevention (CDC) recommendation for the COVID-19 vaccine is from September 19, 2025. The U.S. Department of Health and Human Services (HHS) released a press release stating that the new recommendation was backed by both organizations, which “unanimously recommended that vaccination for COVID-19 be determined by individual decision-making.”

The recommendation of individual decision-making applies to all individuals six months and older. However, as with many recommendations, there is an emphasis that vaccination in individuals under age 65 is most favorable for those who are at an increased risk for severe COVID-19 and least favorable for individuals who are not at an increased risk, according to the CDC’s list of COVID-19 risk factors.

To learn more about the current ACIP and CDC COVID-19 vaccine recommendations, which groups of patients are at higher risk for severe COVID-19, and COVID-19 disease information, click the links below.

If you have any questions about prebooking your clinic’s COVID-19 vaccines for the 2026-2027 season or are interested in becoming a PCA member, please email Amy Bullock at abullock@primarycarealliance.com or call her at (801) 369-3933.

Does your clinic still have leftover flu or COVID-19 vaccine doses from this season? Read our blog post on how to return unused vaccine doses.

How to Return COVID and Flu Vaccines — 2025-2026 Season

2025-2026 COVID-19 and Flu Vaccine Return Information

If you have COVID-19 vaccine doses or flu vaccine doses left over from this past season, now is the time to return them. To assist our members with returning their leftover COVID-19 and flu vaccine doses, we’ve listed instructions and resources for each manufacturer below. Returns do not need to be refrigerated. Please note that each manufacturer has a specific deadline. Once you have returned your vaccines, please allow 4-6 weeks for processing time.

Moderna COVID-19 Vaccine Return Information –

If the customer purchased Moderna COVID-19 vaccines for the 2025-2026 season through www.ModernaDirect.com, please click here for directions on obtaining a Return Authorization (RA) from Inmar. Once you receive the RA from Inmar, the customer is responsible for shipping the vaccine to Inmar. Moderna has two return windows. The first return window ends May 31, 2026. The second return window ends October 31, 2026. Credits will NOT be issued until after the close of each respective returns window.

If the customer purchased Moderna COVID-19 vaccines for the 2025-2026 season through a distributor, please contact the distributor for information on returning unused COVID-19 vaccines. Each distributor will have its own return policy and return deadlines.

Pfizer COVID-19 Vaccine Return Information –

If the customer purchased Pfizer COVID-19 vaccines for the 2025-2026 season, please click here for directions on returning Pfizer COVID-19 vaccines. All returns must be received prior to September 15, 2026.

CSL Seqirus Flu Vaccine Return Information –

Customers must complete the return requests by June 10, 2026, after which the product must be received by Inmar no later than June 28, 2026.

If the customer has a direct account with Inmar, they can log into their www.flu360.com account. On the right side of the screen, click on “Orders” then “Returns.”  Please click here for CSL Seqirus Influenza Vaccine Returns FAQ and checklist.

If the customer does not have a direct account with Inmar, please click here to download the return form.

Sanofi Flu Vaccine Return Information –

Sanofi customers are eligible to return up to 15% of their shipped influenza reservation by presentation. Returns exceeding the allowable thresholds will receive a federal excise tax credit only. To get started, log in to www.VaccineShop.com/returns  or select “Returns” from the navigation bar at the top of the screen. Refer to this Quick Guide from Sanofi for additional information by clicking here.

For additional assistance, you can also reference the many resources available, including Vaccine Shop’s Returns Help Center , which has many short instructional videos, such as: Help Me With My Return or What’s My Return Status Mean?

Please note all eligible influenza returns must be physically received by Inmar no later than July 31, 2026, otherwise credit will be given for federal excise tax only. We encourage you to send your return immediately upon expiration for timely processing. 

If the customer has a direct account with Inmar, they can log into their www.flu360.com account. On the right side of the screen, click on “Orders” then “Returns.”  Please click here for CSL Seqirus Influenza Vaccine Returns FAQ and checklist.

If you have any questions after reviewing the resources above, please email Amy Bullock at abullock@primarycarealliance.com or call her at (801) 369-3933.

Address

240 N. East Promontory Suite 200
Farmington, UT 84025

Directions

CONTACT US

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
*